| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.090 | Biomarker | phenotype | BEFREE | In addition, DS-437 significantly enhanced the anti-tumor effects of anti-erbB2/neu monoclonal antibody targeted therapy in Balb/c mice bearing CT26Her2 tumors by inhibiting Treg function and induction of tumor immunity. | 30800128 | 2019 | ||||
|
0.090 | Biomarker | phenotype | BEFREE | A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. | 30665463 | 2019 | ||||
|
0.090 | Biomarker | phenotype | BEFREE | The anti-neu antibody inhibited tumor growth and enhanced anti-tumor immunity in HER2/neu+ breast cancer TUBO models, whereas GDC-0941 or A66 alone did not. | 29721370 | 2018 | ||||
|
0.090 | Biomarker | phenotype | BEFREE | However, autoimmune tolerance prevents vaccines based on HER2 protein from inducing long-lasting, highly effective anti-tumor immunity. | 29778570 | 2018 | ||||
|
0.090 | AlteredExpression | phenotype | BEFREE | Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming. | 20924101 | 2010 | ||||
|
0.090 | Biomarker | phenotype | BEFREE | The development of Her-2 DNA vaccine has progressed through three phases that can be categorized as phase "A": the pursuit of Her-2 as a tumor-associated "antigen", phase "B": tilting the "balance" between tumor immunity and autoimmunity and phase "C": the on-going "clinical trials". | 18273615 | 2008 | ||||
|
0.090 | Biomarker | phenotype | BEFREE | Immunization with recombinant Her2 protein alone, or loaded on DCs, did not induce tumor immunity. | 17268793 | 2007 | ||||
|
0.090 | Biomarker | phenotype | BEFREE | HER-2 specific tumor immunity relied completely on both CD4+ and CD8+ T cells. | 14750178 | 2004 | ||||
|
0.090 | Biomarker | phenotype | BEFREE | Therefore, cytE2A appears to induce anti-tumor immunity without an Ab response. | 11544306 | 2001 |